Hinge Health Inc. Class A Common Stock vs Trip.com Group Ltd — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Trip.com Group Ltd trades at $39.37 (market cap $24.60B). The key difference: Trip.com Group Ltd is far larger — about 2.9× Hinge Health Inc. Class A Common Stock's market cap, and Trip.com Group Ltd pays a 0.42% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Trip.com Group Ltd for 80 Days on average.
| HNGE | TCOM | |
|---|---|---|
Market Cap | $8.48B | $24.60B |
Volume | 879,799 | 1,981,955 |
Sector | Health | Consumer Cyclical |
52-Week High | $105.14 | $78.96 |
52-Week Low | $31.17 | $37.96 |
Typical Hold Time | 0 Days | 80 Days |
Enterprise Value | $8.10B | $16.75B |
Dividend Yield | — | 0.42% |
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
TCOM trades at $38.88, up 0.31% on the day, with a bearish technical signal and neutral oscillators. The stock shows strong fundamentals with a P/E of 7.48, net income margin of 36.9%, and robust revenue growth from $20.0B in 2022 to $62.4B in 2025. Recent Q2 2026 earnings beat expectations at $1.07 per share, though Q1 and Q4 2025 missed. Cash flow remains positive with $7.11B net cash flow in 2024, and the balance sheet is healthy with total assets of $242.58B and debt-to-asset ratio improving to 16.37%.
The outlook is mixed: analyst consensus is bullish with a $56.64 price target and 70.45% buy ratings, but regulatory risks and recent antitrust fines pose challenges. Earnings growth and international expansion are key catalysts, yet competition and market volatility require caution. The stock presents value given low valuations, but investors must weigh regulatory headwinds against fundamental strength.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →